Welcome to our dedicated page for Equillium SEC filings (Ticker: EQ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Equillium, Inc. (Nasdaq: EQ) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Equillium is a clinical-stage biotechnology company based in La Jolla, California, focused on developing immunomodulatory therapies for severe autoimmune and inflammatory disorders, with its lead candidate EQ504 targeting the aryl hydrocarbon receptor (AhR).
Through this page, users can review Form 10-Q and 10-K reports, which include details on Equillium’s operating losses, cash resources, going concern language from auditors, and management’s discussion of risks and plans related to its immuno-inflammatory pipeline and financing needs. Form 8-K filings document material events such as private placement agreements to fund EQ504 development, amendments to at-the-market sale agreements, changes in independent registered public accounting firms, leadership and board updates, and the termination of collaboration and license agreements related to itolizumab with Biocon Limited.
Equillium’s filings also cover Nasdaq listing matters, including notices of non-compliance with minimum bid price requirements and subsequent confirmation of regained compliance. Additional disclosures describe the company’s adoption of a cryptocurrency treasury reserve strategy, amendments to its investment policy, and supplemental risk factors associated with digital asset holdings.
On Stock Titan, these documents are updated in near real time as they appear on EDGAR. AI-powered summaries help explain complex sections, highlight key points on topics such as EQ504 development plans, capital structure changes, and treasury strategy, and make it easier to identify items like equity issuances, open market sale agreements and auditor changes. Users can also quickly locate Form 4 and other ownership-related filings to track insider and major holder activity as it is reported.
Equillium, Inc. filed a shelf registration on Form S-3 to offer up to $250,000,000 of securities (common stock, preferred stock, debt, and warrants) from time to time, with terms to be set by prospectus supplements. The filing also includes a dedicated sales agreement prospectus for an at-the-market offering of up to $75,000,000 of common stock through LifeSci Capital, included within the $250,000,000 shelf.
Under the ATM, LifeSci Capital will act as sales agent on a commercially reasonable efforts basis, and will receive up to 3.0% of gross proceeds as compensation. Proceeds to the company will be used for general corporate purposes, including research and development, working capital, and capital expenditures, as later specified in supplements.
Equillium’s common stock trades on Nasdaq as “EQ,” and the last reported sale price was $0.924 per share on November 12, 2025. Shares outstanding were 60,676,837 as of September 30, 2025; this is a baseline figure, not the amount being offered.
Equillium, Inc. (EQ) reported a Q3 net loss of $4.23 million with $0 revenue, compared with $12.16 million in revenue a year ago tied to a now‑ended Ono arrangement. Operating expenses were $4.58 million versus $12.84 million last year, reflecting a smaller cost base post‑transition.
Cash and cash equivalents were $33.12 million and stockholders’ equity totaled $30.94 million. The company closed an August 2025 private placement for ~$30 million gross (common stock and pre‑funded warrants), and may raise up to an additional ~$20 million upon clinical and price‑based milestones. During Q3, it also sold shares via its ATM facility for ~$0.9 million gross. Shares outstanding were 60,676,837 at September 30, 2025, and 60,893,283 as of November 10, 2025.
The company terminated prior Biocon agreements and is focusing on EQ504, an aryl hydrocarbon receptor modulator, with an intended Phase 1 proof‑of‑mechanism study by mid‑2026. Management indicates existing cash is expected to fund operations through 2027.
Equillium, Inc. furnished an 8‑K announcing financial results for the third quarter ended September 30, 2025, via a press release attached as Exhibit 99.1. The company states the information under Item 2.02, including the exhibit, is furnished and not deemed filed under Section 18 of the Exchange Act, and it is not incorporated by reference into other SEC filings except as expressly specified by reference.
Equillium, Inc. filed an amended report to update its previously disclosed change in independent auditor. The company confirms that Crowe LLP has now completed its client acceptance procedures and, on October 21, 2025, executed an engagement letter to serve as Equillium’s independent registered public accounting firm for the fiscal year ending December 31, 2025.
The company states that during the two most recent fiscal years ended December 31, 2024 and December 31, 2023, and through October 21, 2025, it did not consult with Crowe on specific accounting treatments, potential audit opinions, or any issues involving disagreements or reportable events under SEC rules.
Equillium, Inc. filed a Form 8-K reporting a letter from independent auditor KPMG LLP dated October 6, 2025. The company states that KPMG reported no disagreements with management on accounting principles, financial statement disclosure, or audit scope, and identified no reportable events as defined under Regulation S‑K. A copy of KPMG's letter is attached as Exhibit 16.1. The filing also notes the Cover Page Interactive Data File is embedded with the Inline XBRL document. The report is signed by Bruce D. Steel, Chief Executive Officer.
Equillium, Inc. has filed a prospectus supplement for an at-the-market offering of shares of its common stock with an aggregate offering price of up to $75,000,000 under its existing Open Market Sale Agreement with LifeSci Capital LLC.
This prospectus supplement updates and expands a prior program that had covered up to $21,950,000 of common stock. Equillium has already sold 1,719,485 shares for aggregate gross proceeds of $0.96 million under the agreement. A legal opinion from Cooley LLP on the validity of the shares is included as an exhibit.
Equillium, Inc. reports an estimated public float of $93.7 million, calculated from 47,085,662 shares held by non-affiliates and a per‑share price of $1.99. The $1.99 price was the highest closing price on The Nasdaq Capital Market within 60 days of this prospectus supplement's filing, specifically on September 11, 2025. The public float figure follows the method in General Instruction I.B.6 of Form S-3 under the Securities Act of 1933.
The company notes this figure is specific to the current filing and that if it later becomes subject to the limitations in General Instruction I.B.6, it will file another supplement to update the ATM prospectus. No other financial results, transactions, or forward-looking statements are provided in this excerpt.
Equillium, Inc. filed a Form S-8 registration statement to register additional shares of common stock for issuance under its 2018 Equity Incentive Plan and 2018 Employee Stock Purchase Plan. The filing relies on General Instruction E, which allows the company to increase the number of securities for existing employee benefit plans by incorporating prior effective S-8 registration statements by reference. The document also lists standard corporate and legal exhibits, including the company’s charter, bylaws, equity plans, legal opinions, auditor consent, and a filing fee table, and is signed by the chief executive officer and the full board of directors.
Equillium, Inc. filed an S-3 shelf registration to register common stock for resale by selling stockholders, including shares issuable upon exercise of pre-funded warrants sold in a recent private placement. The prospectus identifies multiple institutional holders (including Adage, ADAR1 Entities, Coastlands Capital and Janus) and shows specific share counts and warrants subject to beneficial ownership blockers that exclude certain exercisable shares from pre-offering ownership figures. The filing lists exhibits (e.g., merger agreement, charter documents, Registration Rights Agreement dated August 12, 2025 and pre-funded warrant form dated August 11, 2025) and incorporates prior SEC reports by reference. The total filing fee shown aggregates to $81,562.
Equillium, Inc. has regained compliance with Nasdaq’s minimum bid price requirement for its common stock. Nasdaq notified the company on August 29, 2025 that it once again meets Listing Rule 5550(a)(2) for continued inclusion on The Nasdaq Capital Market. Equillium had previously received notices in December 2024 and June 2025 that its shares were below the $1.00 per share bid price requirement, with an additional 180-day grace period granted in June. The company met the rule by maintaining a closing bid price of at least $1.00 per share for 10 consecutive business days, a condition that was satisfied on August 28, 2025.